News Release Details

Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments

July 14, 2017 at 4:14 PM EDT

-- Avid Achieves Year-Over-Year Topline Revenue Growth of 30% Exceeding $57 Million --

Overall Survival in Phase III SUNRISE Subgroup Receiving Subsequent Immune Checkpoint Inhibitors
Modified from Kallinteris NL et. al., AACR 2017

-- Recent Presentation Supports Bavituximab's Potential to Improve Clinical Outcome for Immune Checkpoint Inhibitors --

TUSTIN, Calif., July 14, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced financial results for the fourth quarter and fiscal year (FY) ended April 30, 2017, and provided an update on its contract manufacturing operations, research and development programs, and other corporate highlights.

Highlights Since January 31, 2017
"We are very pleased to announce that the business recorded its highest annual revenue to date during fiscal 2017," stated Steven W. King, president and chief executive officer of Peregrine, and president of Avid Bioservices.  "While we are happy to report continued year-over-year revenue growth, we are projecting revenues for FY 2018 to be similar with FY 2017 due to recent changes in the forecast of a large customer and a delayed regulatory filing for another customer.  We believe this is a temporary lull and remain confident that Avid is in a strong position for continued growth in the future."  Mr. King continued, "An important part of continuing revenue growth and reducing risk for the business is to attract new customers.  On that front, we have recently signed four new customers that we expect to contribute to top-line revenue in FY 2018 and into the future.  In addition, we successfully completed three process validation campaigns this fiscal year for existing third-party customers which we believe may significantly contribute to future revenue as these customers move toward building inventory for their potential launch, and commercial supply.

"We are also continuing to take other important steps to ensure Avid's growth in the coming years.  As part of this effort, we have recently installed two new 2,000 liter bioreactors in our Myford facility, and we already have commitments for part of this capacity.  Due to its state-of-the-art and modular design, there remains potential to install additional bioreactors in Myford, which will allow us to continue growing the business within our current facilities.

"Turning to the Peregrine business, we were able to generate some of the most compelling bavituximab data to date, further supporting the combination of bavituximab and checkpoint inhibitors even while reducing R&D spending by over 50% in FY 2017.  The clinical findings came from the comprehensive analysis of maturing Phase III SUNRISE data while impressive preclinical results came from our collaborators at Memorial Sloan Kettering Cancer Center (MSKCC). The researchers at MSKCC presented promising preclinical data combining PS-targeting with adoptive T cell transfer therapy which may support the combination of bavituximab with CAR-T cell immunotherapy in the future.

"Both Peregrine and Avid have achieved important milestones in recent quarters.  The success of Avid and its continued revenue growth with the compelling data we have seen from the Phase III SUNRISE trial have led us to explore various strategic options that we believe will enable us to enhance stockholder value for all stockholders, including the possible separation of these two distinct businesses."

Research and Development Highlights
"The most compelling data to date from the Phase III SUNRISE trial was presented at AACR and together with the PD-L1 results presented at ASCO this year add to the growing body of data supporting the further development of bavituximab with checkpoint inhibitors," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine.

AACR Highlights: 
In a subgroup analysis, Peregrine researchers looked at the outcome of 91 patients that were enrolled in the Phase III SUNRISE trial that were subsequently treated with anti-PD-1/PD-L1 immune checkpoint inhibitors ("ICI's") post study treatments.  The results from this analysis demonstrated that the patients who received docetaxel plus bavituximab (Doc+Bavi) and subsequent ICI had not yet reached median overall survival ("mOS") compared to mOS of 13.0 months for patients who received docetaxel plus placebo (Doc+Placebo) (hazard ratio [HR], 0.43; p=0.005).  The statistically significant difference between the two arms in the trial provides strong rationale for combining bavituximab with ICI's and supports the hypothesis that bavituximab may modulate the tumor microenvironment to enhance the anti-tumor activity of ICI's.

A photo accompanying this announcement is available at

ASCO Highlights:
Peregrine researchers presented additional supportive data demonstrating that patients in the bavituximab containing arm who had low baseline PD-L1 expression on tumor cells (i.e., patients typically with poorer response to PD-1/PD-L1 checkpoint inhibitors) lived significantly longer than patients with high baseline PD-L1 expression.  These data further support the hypothesis that bavituximab may modulate the tumor microenvironment to complement and enhance the anti-tumor activity of ICI's.

NCCN Highlights:
The three clinical trials under the collaboration with the NCCN are advancing as planned.

  • Massachusetts General Hospital Cancer Center—Phase I/II Clinical Trial of Bavituximab with Radiation and Temozolomide for Patients with Newly Diagnosed Glioblastoma.  This trial is open for enrollment.
  • Moffitt Cancer Center—A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy for Unresectable Hepatitis C Associated Hepatocellular Carcinoma.  This trial is open for enrollment.
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins—Phase II Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.  This trial is expected to be initiated by the end of the calendar year 2017.

Preclinical Highlights:
Researchers from Memorial Sloan Kettering Cancer Center (MSKCC) presented a preclinical study evaluating the anti-tumor activity and toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies or anti-OX40 antibodies in mice with advanced melanomas.  Whereas PS-targeting and anti-OX40 demonstrated comparable tumor regression when administered in combination with transferred adoptive T cells, only the PS-targeting combination achieved these results without any off-target toxicities.  In contrast, the anti-OX40 treatment combination triggered off-target side effects.

PS Exosome Technology Highlights:
The company continues to make progress with its PS exosome diagnostic technology that is designed to detect and monitor cancer.  The assay has been successfully optimized and we are currently preparing to generate additional data by testing human samples.  Such data will be important to partnering discussions.

Avid Bioservices Highlights
"FY 2017 was a strong year for Avid Bioservices with year-over-year revenue growth of 30% compared to FY 2016.  The company recognized revenue of $17.9 million for the fourth quarter and $57.6 million for the full fiscal year," stated Paul Lytle, chief financial officer of Peregrine.  "While we missed our revenue guidance of $60 to $65 million, we were ready to ship a number of process validation runs which were delayed due to events outside our control.  This delay has caused approximately $10 million in manufacturing revenue to shift from fiscal year 2017 to fiscal year 2018."

  • The company is providing manufacturing revenue guidance for the full FY 2018 of $50 million - $55 million.
  • Avid's current manufacturing revenue backlog is $58 million, representing estimated future manufacturing revenue to be recognized under committed contracts.  Most of the backlog is expected to be recognized during FY 2018.

Financial Highlights and Results

  • During the fourth quarter of FY 2017, we recorded total revenues of $17,904,000 as compared to $18,783,000 in the fourth quarter of the prior FY.  For FY 2017, we achieved total revenues of $57,630,000 as compared to $44,686,000 for FY 2016.  This represents total revenue growth of 29% for FY 2017 compared to the same prior year period.
  • Contract manufacturing revenue from Avid's clinical and commercial biomanufacturing services was $17,904,000 for the fourth quarter of FY 2017 compared to $18,783,000 for the fourth quarter of FY 2016.  For the year, revenue increased 30% to $57,630,000 for FY 2017 compared to $44,357,000 for FY 2016. The fiscal year increase was primarily attributed to an increase in demand for contract manufacturing services associated with process validation activities. Current committed manufacturing backlog for Avid is approximately $58 million, covering services to be provided during FY 2018 and into FY 2019.  Based on this current backlog, Peregrine expects contract manufacturing revenue for FY 2018 to be between $50 and $55 million.
  • Total costs and expenses for the fourth quarter of FY 2017 were $23,208,000, compared to $30,698,000 for the fourth quarter of FY 2016.  For FY 2017, total costs and expenses were $85,890,000 compared to $101,046,000 for FY 2016.  For the fourth quarter of FY 2017, research and development expenses decreased 59% to $6,717,000, compared to $16,265,000 for the fourth quarter of FY 2016.  For FY 2017, research and development expenses decreased 52% to $28,297,000 compared to $59,529,000 for FY 2016. 
  • Cost of contract manufacturing increased to $11,782,000 in the fourth quarter of FY 2017 compared to $9,721,000 for the fourth quarter of FY 2016, and to $38,259,000 for the full FY 2017 as compared to $22,966,000 for the full FY 2016.  These increases are primarily due to an increase in the cost of contract manufacturing associated with higher reported revenue.  Also contributing to this increase and impacting gross margins for the period is the higher overhead cost of operating the new Myford facility as well as higher labor cost associated with performing process validation runs combined with lower utilization of available capacity.  For the fourth quarter of FY 2017, selling, general and administrative expenses decreased slightly to $4,709,000 compared to $4,712,000 for FY 2016.  For FY 2017 selling, general and administrative expenses increased to $19,334,000 compared to $18,551,000 for FY 2016.  The full-year increase is primarily due to the company's growing manufacturing business.
  • Peregrine's consolidated net loss attributable to common stockholders was $6,714,000 or $0.16 per share, for the fourth quarter of FY 2017, compared to a net loss attributable to common stockholders of $13,264,000, or $0.40 per share, for the same prior year quarter.   For FY 2017, net loss attributable to common stockholders was $32,799,000, or $0.88 per share, compared to $60,136,000, or $1.95 per share, for FY 2016.
  • Peregrine reported $46,799,000 in cash and cash equivalents as of April 30, 2017, compared to $61,412,000 at fiscal year ended April 30, 2016.

More detailed financial information and analysis may be found in Peregrine's Annual Report on Form 10-K, which will be filed with the Securities and Exchange Commission today.

Conference Call
Peregrine will host a conference call and webcast this afternoon, July 14, 2017, at 4:30 PM EDT (1:30 PM PDT).

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals conference call. To listen to the live webcast, or access the archived webcast, please visit:

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products.  Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers.  The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer.  For more information, please visit .

About Avid Bioservices
Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that a future clinical trial combining bavituximab with an immune checkpoint inhibitor my not generate statistically significant data,  data consistent with the data presented at AACR regarding SUNRISE patients who were treated with bavituximab and subsequently treated with immune checkpoint inhibitors or data supporting the theory that bavituximab modulates the tumor microenvironment to complement and enhance anti-tumor activity of immune checkpoint inhibitors, the risk that one or more of the NCCN grant funded investigator-initiated clinical studies may experience  enrollment delays, the risk that data from one or more of the NCCN grant funded investigator-initiated clinical studies does not support further evaluation, the risk that the results from the pre-clinical studies are not replicated in human clinical trials, the risk that the company may not have or raise adequate financial resources from debt and/or equity financings and/or Avid's manufacturing operations to enable it to continue as a going concern, or to fund the further development of bavituximab or further development of PS exosome diagnostic technology, the risk that data from further testing of the PS exosome diagnostic with human samples will not support further development, commercialization or contemplated partnering discussions, the risk that Avid's revenue growth may slow or decline, the risk that the company does not achieve profitability, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers, revenue recognition and receipt of payment, the risk that one or more existing Avid customers terminates its contract prior to completion or reduces or delays its demand for manufacturing services, and the risk that commencement of construction of the new manufacturing facility will be delayed indefinitely due to a lack of customer demand and/or inability to raise the capital to construct the facility.  The company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2017 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. 

  2017   2016   2017   2016 
 Unaudited Unaudited    
Contract manufacturing revenue$17,904,000  $18,783,000  $57,630,000  $44,357,000 
License revenue          329,000 
Total revenues 17,904,000   18,783,000   57,630,000   44,686,000 
Cost of contract manufacturing 11,782,000   9,721,000    38,259,000   22,966,000 
Research and development 6,717,000   16,265,000   28,297,000    59,529,000 
Selling, general and administrative 4,709,000   4,712,000   19,334,000   18,551,000 
Total costs and expenses 23,208,000   30,698,000   85,890,000   101,046,000 
LOSS FROM OPERATIONS (5,304,000 )  (11,915,000)  (28,260,000)  (56,360,000)
Interest and other income 37,000   31,000   108,000   722,000 
Interest and other expense (5,000)     (7,000)  (14,000)

$(5,272,000) $(11,884,000) $(28,159,000) $(55,652,000)
COMPREHENSIVE LOSS $(5,272,000) $(11,884,000) $(28,159,000) $(55,652,000)
Series E preferred stock accumulated dividends (1,442,000)  (1,380,000)  (4,640,000)  (4,484,000)



 $  (60,136,000

Basic and Diluted (1) 42,141,720   33,478,863  37,109,493   30,895,089 
BASIC AND DILUTED LOSS PER COMMON SHARE (1)$(0.16) $(0.40) $(0.88) $(1.95)

(1)  All share and per share amounts of our common stock issued and outstanding for all periods have been retroactively adjusted to reflect the one-for-seven reverse stock split which took effect with the opening of trading on July 10, 2017.

AS OF APRIL 30, 2017 AND 2016
 2017 2016
Cash and cash equivalents$  46,799,000  $  61,412,000 
Trade and other receivables   7,742,000     2,859,000 
Inventories   33,099,000     16,186,000 
Prepaid expenses   1,460,000     1,351,000 
  Total current assets   89,100,000     81,808,000 
Leasehold improvements   20,098,000     19,610,000 
Laboratory equipment   10,777,000     10,257,000 
Furniture, fixtures, office equipment and software   4,499,000     4,045,000 
    35,374,000     33,912,000 
Less accumulated depreciation and amortization   (11,700,000)    (9,610,000)
  Property and equipment, net   23,674,000     24,302,000 
Restricted cash   1,150,000     600,000 
Other assets   4,188,000     2,333,000 
TOTAL ASSETS$  118,112,000  $  109,043,000 

AS OF APRIL 30, 2017 AND 2016 (continued)
 2017 2016
Accounts payable$  5,779,000  $  8,429,000 
Accrued clinical trial and related fees   4,558,000     7,594,000 
Accrued payroll and related costs   6,084,000     5,821,000 
Deferred revenue   28,500,000      10,030,000 
Customer deposits   17,017,000     24,212,000 
Other current liabilities   993,000     1,488,000 
  Total current liabilities   62,931,000     57,574,000 
Deferred rent, less current portion   1,599,000     1,395,000 
Commitments and contingencies   
Preferred stock - $.001 par value; authorized 5,000,000 shares;
issued and outstanding - 1,647,760 and 1,577,440, respectively
   2,000     2,000 
Common stock - $.001 par value; authorized 500,000,000
shares; issued and outstanding - 44,014,040 and 33,847,213,
   44,000     34,000 
Additional paid-in-capital   590,971,000     559,314,000 
Accumulated deficit   (537,435,000)    (509,276,000)
  Total stockholders' equity   53,582,000     50,074,000 

 (1)  All share and per share amounts of our common stock issued and outstanding for all periods have been retroactively adjusted to reflect the one-for-seven reverse stock split which took effect with the opening of trading on July 10, 2017.

The photo is also available at Newscom,, and via AP PhotoExpress.


Stephanie Diaz (Investors)                   

Vida Strategic Partners                        


Tim Brons (Media)

Vida Strategic Partners


Primary Logo

Source: Peregrine Pharmaceuticals Inc.

News Provided by Acquire Media